A new study from the University of Liverpool significantly advances the understanding of Alzheimer’s disease. Researchers ...

A loss of brain volume associated with new immunotherapies for Alzheimer's disease may be caused by the removal of amyloid ...

The members of the Amyloid imaging to prevent Alzheimer's disease (AMYPAD) have announced the publication of a perspective ...

Disease Monitoring. Which method is better? Basically, there are two approved methods for identifying the presence of dangerous amyloid plaques in the brains of Alzheimer's patients. Method number ...

APOE4 carriers had higher blood-brain barrier permeability, even without cognitive decline or amyloid beta buildup, ...

Cardiac amyloidosis is a myocardial disease characterized by extracellular amyloid infiltration throughout the heart. Cardiac amyloidosis has a wide spectrum of clinical manifestations but the ...

Alzheimer’s disease, the most common form of dementia, affects millions of people worldwide, slowly robbing them of their ...

Brain volume loss linked to new Alzheimer’s immunotherapies, such as lecanemab, is caused by the removal of amyloid plaques rather than neuronal damage.

UK: A recent retrospective cohort study has highlighted the critical role of kidney function in patients diagnosed with ...

The International Working Group discussed diagnosing Alzheimer's disease among cognitively unimpaired individuals in a ...

Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble ...